BREAST STUDIES USON 10-195 "Call Project Manager"
A Phase 1/2 Dose-Escalation Study of XL147 or XL765 in Combination with Letrozole in subjects with Hormone
"Arm 1 opened 02/16/12"
Receptor-Positive and HER2-Negative Breast Cancer refractory to a Nonsteroidal Aromatase Inhibitor (XL147-202). Locally Recurrent/Metastatic USON 11-086
A Phase 3 Open-Label, Randomized, Multicenter Study Of NKTR-102 Versus Treatment Of Physician's ChoiceTPC) In Patients With Locally Recurrent Or Metastatic Breast Cancer Previously Treated With An Anthracycline, A Taxane, And Capecitabine (The BEACON Study)
Metastatic 1/2/3 Line USON 09-097 Post Trastuzumab
A randomized, Phase III, Open-label study of Lapatinib plus Trastuzumab versus Trastuzumab as continued HER2 suppression therapy after completion of 1st/2nd line Trastuzumab plus chemo in subjects with HER2 Positive Metastatic BC. Neo-Adjuvant USON 10-121
Prediction of Response to Neoadjuvant Chemotherapy in Women with Operable Breast Cancer (PT-304)
COLON STUDIES Metastatic 2nd Line USON 10-101 "Enrollment On Hold"
Randomized, Double-blind, Multicenter Phase III study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) PlusRamucirumab or Placebo in patients with Metastatic Colorectal Carcinoma Progressive During or Following 1st- line combotherapy with Bevacizumab, Oxaliplatin and a Fluoropyrimidine.
LUNG: NSCLC Advanced First Line Therapy USON 08-035
A randomized, double blinded, Placebo-controlled study to evaluate the long-term safety and efficacy of Darbepoetin Alfain anemic subjects with advanced stage Non-Small Lung Cancer receiving multi-cycle chemotherapy.
An Open-label, Multicenter, Randomized, Phase II study of a Recombinant Human Anti-VEGFR-2 Monoclonal Antibody, IMC-1121B in combination with Platinum-based chemotherapy versus Platinum-based Chemotherapy alone as first-line treatment of patients with recurrent or advanced NSCLC. "Open to Patients with SQUAMOUS histology only" Second Line Therapy USON 10-061 "Enrollment On Hold"
Protocol I4T-MC-JVBA (also known as IMCL CP12-1027) A Randomized, Double-Blind, Phase 3 Study of Docetaxel and Ramucirumab versus Docetaxel and Placebo in the Treatment of Stage IV Non-Small Cell Lung Cancer Following Disease Progression after One Prior Platinum- Based Therapy.
LYMPHOMA First Line Therapy
An open-label, Randomized, Phase 2 Study to Assess the Effectiveness of RCHOP With or Without VELCADE in previously
untreated patients with Non-Germinal Center B-Cell-like diffuse Large B-Cell Lymphoma. FOLLICULAR LYMPHOMA GSK OMB113676
Study comparing a new drug (Ofatumumab) to treat Follicular Lymphoma with an approved drug (Rituximab). LYMPHOMA (NON-HODGKINS) Relapsed USON 10215
A Randomized Multicenter Study Comparing Pixantrone + Rituximab with Gemcitabine + Rituximab in Patients with Aggressive B-cell Non-Hodgkin Lymphoma Who Have Relapsed after Therapy with CHOP-R or an Equivalent Regimen and are Ineligible for Stem Cell Transplant
MYELODYSPLASTIC SYNDROME USON 09152
A multi-center, randomized, double-blind, placebo-controlled clinical trial of deferasirox in patients with MS(low/int-1 risk) and transfusional iron overload (TELESTO) Protocol Number: CICL670A2302. ORAL CHEMO DELAY PROTOCOL MCA 2011A
Evaluation of Delays in Instituting Oral Chemotherapy
Auto-relato Paulo B. Linhares (nome fictício) Em 1962, estudava interno em um seminário e tinha passadopara o 1º ano do curso clássico (1º ano do 2º grau, hoje) e podiafreqüentar uma sala onde tínhamos permissão de fumar, ler jor-nais e algumas outras regalias. Por isso comprei três maços de ci-garros e quando ia fumar o terceiro cigarro, veio um pensamentoa minha mente como um
The effect of coffee and caffeine consumption on serum lipids in rats.N. Rakicioglu, G. Pekcan and A. Cevik. International Journal of Food Sciences and Nutrition 49.6 (Nov 1998): p441(1). (3575 words) Abstract: Coronary heart disease research confirms that coffee alone is not a significant risk factor. Laboratory rats were fed controlled diets with varying levels of coffee, caffeine